INVITED EDITORIAL
The New Genomics Era: Integration of genomics into mainstream oncology and implications for psycho-oncological care
Elizabeth K. Bancroft,
Kelly Kohut, Rosalind A. Eeles,
Corresponding Author
Elizabeth K. Bancroft
Royal Marsden NHS Foundation Trust, London, UK
The Institute of Cancer Research, London, UK
Correspondence
Elizabeth K. Bancroft, Oncogenetics Team, The Royal Marsden NHS Foundation Trust, Fulham Road, London, 123 Old Brompton Rd, London SW3 6JJ, UK.
Email: [email protected]
Search for more papers by this authorRosalind A. Eeles
The Institute of Cancer Research, London, UK
Royal Marsden NHS Foundation Trust, London, UK
Search for more papers by this authorElizabeth K. Bancroft,
Kelly Kohut, Rosalind A. Eeles,
Corresponding Author
Elizabeth K. Bancroft
Royal Marsden NHS Foundation Trust, London, UK
The Institute of Cancer Research, London, UK
Correspondence
Elizabeth K. Bancroft, Oncogenetics Team, The Royal Marsden NHS Foundation Trust, Fulham Road, London, 123 Old Brompton Rd, London SW3 6JJ, UK.
Email: [email protected]
Search for more papers by this authorRosalind A. Eeles
The Institute of Cancer Research, London, UK
Royal Marsden NHS Foundation Trust, London, UK
Search for more papers by this authorFunding information: NIHR
CONFLICT OF INTEREST
Prof Rosalind Eeles' declaration of interest: (a) GU-ASCO meeting in San Francisco, Jan 2016: honorarium as speaker $500; (b) Royal Marsden NHS Foundation Trust talk (title: Genetics and Prostate Cancer), November 2017: £1100 support from Janssen; and (c) University of Chicago invited talk, May 2018: honorarium as speaker $1000.
Open Research
DATA AVAILABILITY STATEMENT
N/A
REFERENCES
- 1 NHS Confederation. Our inheritance, our future: realising the potential of genetics in the NHS (DOH white paper) [Online]; 2003. http://publichealthwell.ie/node/24350. Accessed October 24, 2019.
- 2Shendure J, Findlay GM, Snyder MW. Genomic medicine—progress, pitfalls, and promise. Cell. 2019; 177(1): 45-57.
- 3 Chief Medical Officer Annual Report. Generation genome; 2016. https://www.gov.uk/government/publications/chief-medical-officer-annual-report-2016-generation-genome. Accessed October 24, 2019.
- 4Turnbull C, Scott RH, Thomas E, et al. The 100 000 Genomes project: bringing whole genome sequencing to the NHS. BMJ. 2018; 361:k1687.
- 5Scott RH, Fowler TA, Caulfield M. Genomic medicine: time for health-care transformation. Lancet. 2019; 394(10197): 454-456. https://doi.org/10.1016/S0140-6736(19)31796-9.
- 6Snape K, Wedderburn S, Barwell J. The new genomic medicine service and implications for patients. Clin Med (Lond). 2019; 19(4): 273-277. https://doi.org/10.7861/clinmedicine.19-4-273.
- 7Kohut K, Limb S, Crawford G. The changing role of the genetic counsellor in the genomics era. Curr Genet Med Rep. 2019; 7: 75-84. https://doi.org/10.1007/s40142-019-00163-w.
10.1007/s40142-019-00163-w Google Scholar
- 8George A, Riddell D, Seal S, et al. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep. 2016; 6:29506. https://doi.org/10.1038/srep29506.
- 9Kentwell M, Dow E, Antill Y, et al. Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer cancer clinics. Gynecol Oncol. 2017; 145(1): 130-136. https://doi.org/10.1016/j.ygyno.2017.01.030 [Epub 2017 Feb 3].
- 10Høberg-Vetti H, Eide GE, Siglen E, et al. Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling. Acta Oncol. 2019; 58(2): 175-181. https://doi.org/10.1080/0284186X.2018.1502466.
- 11Rahman B, Lanceley A, Kristeleit R, et al. Mainstreamed genetic testing for women with ovarian cancer: first-year experience. J Med Genet. 2019; 56(3): 195-198. https://doi.org/10.1136/jmedgenet-2017-105140 [Epub 2018 Mar 13].
- 12Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018; 379(26): 2495-2505. https://doi.org/10.1056/NEJMoa1810858 [Epub 2018 Oct 21].
- 13Mandelker D, Donoghue M, Talukdar S, et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Annals Oncol. 2019; 30(8): 1221-1231.
- 14Nilsson MP, Nilsson ED, Borg Å, Brandberg Y, Silfverberg B, Loman N. High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study. Breast Cancer Res Treat. 2019; 173(2): 313-318. https://doi.org/10.1007/s10549-018-5000-y.
- 15Nilsson MP, Törngren T, Henriksson K, et al. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer. Breast Cancer Res Treat. 2018; 168(1): 117-126. https://doi.org/10.1007/s10549-017-4584-y.
- 16Kemp Z, Turnbull A, Yost S, et al. Evaluation of cancer-based criteria for use in mainstream BRCA1 and BRCA2 genetic testing in patients with breast cancer. JAMA NetwOpen. 2019; 2(5):e194428. https://doi.org/10.1001/jamanetworkopen.2019.4428.
- 17Eccleston A, Bentley A, Dyer M, et al. A cost-effectiveness evaluation of germline BRCA1 and BRCA2 testing in UK women with ovarian cancer. Value Health. 2017; 20(4): 567-576. https://doi.org/10.1016/j.jval.2017.01.004.
- 18Wright S, Porteous M, Stirling D, et al. Patients' views of treatment-focused genetic testing (TFGT): some lessons for the mainstreaming of BRCA1 and BRCA2 testing. J Genet Couns. 2018; 27(6): 1459-1472.
- 19Ahmed M, Rosalind ER. Germline genetic profiling in prostate cancer: latest developments and potential clinical applications. Future Sci OA. 2016; 2(1):FSO87.
- 20Chowdhury S, Dent T, Pashayan N, et al. Incorporating genomics into breast and prostate cancer screening: assessing the implications. Genet Med. 2013; 15(6): 423-432. https://doi.org/10.1038/gim.2012.167.
- 21Bunnik EM, Schermer MH, Janssens AC. Personal genome testing: test characteristics to clarify the discourse on ethical, legal and societal issues. BMC Med Ethics. 2011; 12: 11. https://doi.org/10.1186/1472-6939-12-11).
- 22Forrest LE, Sawyer SD, Hallowell N, James PA, Young MA. High-risk women's risk perception after receiving personalized polygenic breast cancer risk information. J Community Genet. 2019; 10(2): 197-206.
- 23Bancroft EK, Castro E, Bancroft GA, et al. The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. Psychooncology. 2015; 24(11): 1492-1499. https://doi.org/10.1002/pon.3814.
- 24Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329(7456): 15-19.
- 25Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet. 2019; 394(10197): 521-532. https://doi.org/10.1016/S0140-6736(19)31276-0.
- 26Bijlsma RM, Wouters RHP, Wessels H, et al. Managing unsolicited findings in genomics: a qualitative interview study with cancer patients. Psycho-Oncol. 2018; 27: 1327-1333.
- 27Kurian AW, Li Y, Hamilton AS, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. 2017; 35(20): 2232-2239.
- 28 The Topol Review. Preparing the healthcare workforce to deliver the digital future. An independent report on behalf of the Secretary of State for Health and Social Care; 2019. https://topol.hee.nhs.uk/wp-content/uploads/HEE-Topol-Review-2019.pdf. Accessed September 28, 2019.
- 29Josephs KS, Berner A, George A, et al. Genomics: the power, potential and pitfalls of the new technologies and how they are transforming healthcare. Clin Med. 2019; 19(4): 269-272.
- 30Middleton A, Marks P, Bruce A, et al. The role of genetic counsellors in genomic healthcare in the United Kingdom: a statement by the Association of Genetics Nurses and Counsellors. Eur J Hum Genet. 2017; 25: 659-661.
- 31Tung N, Domchek S, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol. 2016; 13(9): 581-588. https://doi.org/10.1136/bmj.k1687.
- 32Ormond KE, Hallquist ML, Buchanan AH, et al. Developing a conceptual, reproducible, rubric-based approach to consent and result disclosure for genetic testing by clinicians with minimal genetics background. Genet Med. 2019; 21(3): 727-735.
- 33Lautenbach DM, Christensen KD, Sparks JA, Green RC. Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genomics Hum Genet. 2013; 14: 491-513. https://doi.org/10.1146/annurev-genom-092010-110722.
- 34Allen CG, Andersen B, Khoury MJ, Roberts MC. Current social media conversations about genetics and genomics in health: a Twitter-based analysis. Public Health Genomics. 2018; 21(1–2): 93-99. https://doi.org/10.1159/000494381.
- 35Middleton A, Niemiec E, Prainsack B, et al. ‘Your DNA, Your Say’: global survey gathering attitudes toward genomics: design, delivery and methods. Per Med. 2018; 15(4): 311-318. https://doi.org/10.2217/pme-2018-0032.
- 36Etchegary H, Cappelli M, Potter B, et al. Attitude and knowledge about genetics and genetic testing. Public Health Genomics. 2010; 13(2): 80-88. https://doi.org/10.1159/000220034.
- 37Ardern-Jones A, Kenen R, Eeles RA. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur J Cancer Care (Engl). 2005; 14(3): 272-281.
- 38Krieger JL, Murray F, Roberts JS, Green RC. The impact of personal genomics on risk perceptions and medical decision-making. Nat Biotechnol. 2016; 34(9): 912-918. https://doi.org/10.1038/nbt.3661.
- 39Rehm HL. Evolving health care through personal genomics. Nat Rev Genet. 2017; 18(4): 259-267. https://doi.org/10.1038/nrg.2016.162.
- 40French DP, Southworth J, Howell A, et al. Psychological impact of providing women with personalised 10-year breast cancer risk estimates. British J Cancer. 2018; 118: 1648-1657.
- 41 Royal College of Physicians, Royal College of Pathologists and British Society for Genomic Medicine. Report of the Joint Committee on Genomics in Medicine. Consent and Confidentiality in Genomic Medicine: Guidance on the Use of Genetic and Genomic Information in the Clinic. 3rd ed. London: RCP, RCPath and BSGM: 2019.
Citing Literature
